irinotecan has been researched along with Blood Poisoning in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lovetrue, B | 1 |
| Dasanu, CA; Nandy, N | 1 |
| Gillmore, R; Suarez Martinez-Falero, B | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Bradbury, J; Cave, J; Crabb, SJ; Johnson, PW; Muthuramalingam, SR; Nolan, L; Ottensmeier, C; Selman, D | 1 |
1 trial(s) available for irinotecan and Blood Poisoning
| Article | Year |
|---|---|
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Small Cell Lung Carcinoma; Thrombosis | 2012 |
4 other study(ies) available for irinotecan and Blood Poisoning
| Article | Year |
|---|---|
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.
Topics: Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Illness; Disease Outbreaks; Disease Progression; Drug Discovery; Drug Therapy, Combination; Etoposide; Humans; Irinotecan; SARS-CoV-2; Sepsis; Signal Transduction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Virus Internalization; Virus Replication | 2020 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cholangitis; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Sepsis | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Sepsis | 2014 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |